Riskpilot← Back to searchSign inGet full accessNIH Advokat AB
ABActiveOrg 5591391478StockholmEconomic activity was not specified by tax authority · NACE 0000Est. 20170 employees
Revenue 2025
—
EBITDA margin
—
-1% vs 2024
Equity ratio
77.8%
Financial strength
Net profit 2025
SEK 8,6M
+21% vs 2024
| Revenue | — | — |
| EBITDA | SEK -71K | -1% |
| Net profit | SEK 8,6M | +21% |
| Total assets | SEK 20,5M | +31% |
| Equity | SEK 16M | +118% |
| Employees | 0 | — |
Legal name
NIH Advokat AB
Org number
5591391478
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
13 december 2017
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att driva advokatverksamhet.
Address
Stockholm
Email
niklas.hagbard@msa.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −39 | −46 | −71 | −70 | −71 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −39 | −46 | −71 | −70 | −71 |
| Net financials | 3 906 | 5 155 | 5 791 | 7 218 | 8 732 |
| Profit before tax | 3 866 | 5 188 | 5 720 | 7 148 | 8 661 |
| Tax | −0 | −0 | −0 | −0 | −17 |
| Net profit | 3 866 | 5 188 | 5 720 | 7 148 | 8 645 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 8 565 | 13 563 | 17 078 | 15 627 | 20 513 |
| Equity | 8 529 | 13 533 | 17 065 | 7 313 | 15 957 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 36 | 31 | 13 | 8 314 | 4 555 |
| Total debt | 36 | 31 | 13 | 8 314 | 4 555 |
EBITDA margin
-7055100.0%
This company
15.8%
Market median
-44652632% vs market
20212025
Equity ratio
77.8%
This company
38.2%
Market median
+104% vs market
20212025
Return on equity
54.2%
This company
18.4%
Market median
+195% vs market
20212025
Net profit margin
864457400.0%
This company
8.1%
Market median
+10672313480% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AG Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NIH Advokat AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Gabriella Hermansson | Chief Auditor | 0 companies |
| Gustav Joel Mårtensson | Deputy Board Member | 0 companies |
| Niklas Jacob Filip Hagbard | Board of Directors | 0 companies |